Arterial conduits are increasingly preferred for surgical bypass because of inherent functional properties conferred by arterial endothelial cells, especially nitric oxide production in response to physiologic stimuli. Here we tested whether endothelial progenitor cells (EPCs) can replace arterial endothelial cells and promote patency in tissue-engineered small-diameter blood vessels (4 mm). We isolated EPCs from peripheral blood of sheep, expanded them ex vivo and then seeded them on decellularized porcine iliac vessels. EPC-seeded grafts remained patent for 130 days as a carotid interposition graft in sheep, whereas non-seeded grafts occluded within 15 days. The EPC-explanted grafts exhibited contractile activity and nitric-oxide-mediated vascular relaxation that were similar to native carotid arteries. These results indicate that EPCs can function similarly to arterial endothelial cells and thereby confer longer vascular-graft survival. Due to their unique properties, EPCs might have other general applications for tissue-engineered structures and in treating vascular diseases.
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Cardiovascular disease, including coronary artery and peripheral vascular disease, is the leading cause of mortality in the United States (www.americanheart.org). Surgical replacement or bypass surgery is the most common intervention for coronary and peripheral atherosclerotic diseases with 550,000 bypass cases performed per year (www.americanheart.org). Autologous vessels are the preferred replacement grafts for diseased segments smaller than 5 mm in diameter, but many patients do not have suitable vessels 1 . An alternative approach for small-diameter vessels is to engineer vessels by using scaffolds based on either a biodegradable or decellularized matrix. Previously, in vitro culture of smooth-muscle and endothelial cells on biodegradable or biological scaffold material produced a cellularized vessel with strong mechanical properties, but these grafts developed thrombosis shortly after implantation in vivo [2] [3] [4] . An alternative approach for small-diameter vessels is to allow repopulation of the tissue-engineered graft with host cells in vivo. A decellularized matrix, based either on intestinal collagen or native vessels, was remodeled in vivo with infiltration of host smooth-muscle cells (SMCs) and endothelial cells into the matrix and showed good patency in vivo [5] [6] [7] . One limitation of these studies is that the repopulated endothelial cells were not functional in endothelial-dependent relaxation assays performed on the explanted grafts, which might affect long-term patency rates. Moreover, these results are difficult to extrapolate to humans because endothelial-cell development on vascular grafts occurs more readily in the canine and rabbit models used in the studies 8 . Endothelial cells are a crucial component of the normal vascular wall, providing an interface between the bloodstream and surrounding tissue of the blood vessel wall. Endothelial cells are also involved in physiological events including angiogenesis, inflammation and prevention of thrombosis. In addition to the endothelial cells that compose the vasculature, non-hematologic endothelial progenitor cells (EPCs) circulate in the blood [9] [10] [11] [12] [13] . EPCs migrate to regions of the circulatory system with injured endothelia, including site of traumatic and ischemic injury [14] [15] [16] [17] [18] [19] [20] [21] [22] . In normal adults, the concentration of EPCs in peripheral blood is 2-3 cells/mm, whereas levels are 3.5-fold higher in cord blood 13, 22, 23 . EPCs from peripheral blood are an endothelial-cell source yet to be explored for tissue-engineering cardiovascular structures that require functional endothelia.
We propose that EPCs might be an ideal source of autologous endothelial cells for seeding small-diameter grafts, as removal of a native vessel is unnecessary. By pre-seeding EPCs onto a vascular graft, a non-thrombogenic barrier for the vascular graft might be created, thereby improving the patency rate of the vascular graft in vivo. We tested the feasibility of this approach in the sheep, which is an established model to study cardiovascular structures. In addition, we selected a decellularized graft because these grafts have well-preserved extracellular matrices and mechanical properties resembling native vessels. Furthermore, the decellularized matrix developed thrombosis at high frequency when placed into the carotid position of sheep, consistent with previous vascular graft studies in the sheep and the need to have endothelial cells seeded on the graft prior to implantation 24 .
EPCs from ovine peripheral blood
To obtain EPCs, we took blood samples (15 cc) from 1-to 2-weekold lambs that had no prior stimuli to mobilize EPCs from the bone marrow. We partially purified EPCs using a Histopaque denFunctional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo sity gradient, then plated the leukocyte fraction, which contained EPCs, onto fibronectin-coated plates as described 11 . We serially transferred the cell suspension to new fibronectin-coated plates to remove rapidly adherent hematopoietic cells. After 21 to 28 days in culture, the number of outgrowth colonies ranged between 2 and 3 colonies per 1 × 10 7 total input cells. When allowed to continue growing, the outgrowth cells expanded exponentially and reached 1.6 × 10 9 cells after another 3 weeks. The outgrowth cells exhibited a cobblestone morphology that is characteristic of endothelial cells (Fig. 1a) . The endothelial phenotype was confirmed by immunostaining with antibodies specific for endothelial markers. A representative EPC preparation uniformly expressed CD31 on the cell-cell membrane borders (Fig. 1b) and expressed von Willebrand factor (vWF) in cytoplasmic granules similar to Weibel-Palade bodies (Fig. 1c) . In addition, the EPCs incorporated acetylated low-density lipoprotein (aLDL) (Fig. 1d ). E-selectin was minimally expressed in unstimulated cells (Fig. 1e ), but after stimulation with lipopolysaccharide (LPS) it was significantly upregulated in the EPCs (Fig. 1f) . To further characterize the endothelial phenotype, we analyzed wholecell extracts by immunoblotting with specific antibodies to kinase insert domain receptor (KDR)/Flk-1, the vascular endothelial growth factor (VEGF) receptor-2 and the angiopoietin receptor Tie-2 ( Fig. 1g and h) . The EPCs expressed equivalent amounts of Tie-2 and KDR when compared with human dermal microvascular endothelial cells (HDMEC). We determined the EPC response to VEGF and basic fibroblast growth factor (bFGF) in cellular proliferation assays ( Fig. 1i and j) . Increasing VEGF and bFGF from 0 to 9 ng/ml resulted in 4-fold and 8-fold inductions of cell number, respectively. The proliferative effect of VEGF and bFGF was similar to that seen with HDMEC when using the same experimental assay 25 . Consistent with the endothelial phenotype, the EPCs also formed capillary tubes within 6-12 hours when plated on Matrigel (data not shown). The expression of multiple endothelial markers detected by two different methods and the functional response to physiological stimuli confirmed the endothelial identity of the outgrowth cells. The endothelial phenotype remained constant for 20 passages, demonstrating the stability and feasibility of EPCs for clinical application.
EPC seeding and pre-conditioning in vitro
After we established a consistent procedure for culturing EPCs from peripheral blood of sheep (n = 20), we seeded them onto vascular grafts. We chose decellularized vascular vessels prepared from porcine iliac arteries 4 mm in diameter and 4-5 cm in length. After removal, we incubated the iliac vessels with trypsin, and processed them by an extraction technique using Triton X-100 detergent and ammonium hydroxide. The resultant vessel graft appeared devoid of cellular content, as shown by histological analysis (Fig. 2a) , reverse transcription-PCR assay (data not shown) and the lack of an immune response in mice after implantation of 3-mm 2 pieces of decellularized matrix into the peritoneal cavity (data not shown). In addition, Movat staining demonstrated that the graft had a well-preserved extracellular matrix architecture, including internal and external elastic lamella (Fig. 2b ). After seeding a confluent monolayer of EPCs on the lumen of the graft, we next optimized preconditioning with variations of shear stress to yield the maximal retention of EPCs prior to graft implantation in vivo. Up to 80% of non-preconditioned endothelial cells on expanded polytetrafluoroethylene (ePTFE) grafts are dislodged after exposure to shear stress in vitro or after implantation in vivo 26, 27 , indicating the need for preconditioning the endothelial cells on vascular grafts. We simulated in vivo arterial conditions by subjecting the graft to high shear stress (25 dynes/cm high shear stress resulted in the same cell density of about 32 cells/mm (Fig. 2c , black bar right). Scanning electron microscopy revealed a confluent monolayer of endothelial cells (Fig. 2d) . After we preconditioned the seeded graft, we assessed function of the EPCs by testing their ability to produce nitric oxide (NO). We assayed for NO because of its central role in normal vascular tissue homeostasis [28] [29] [30] [31] [32] [33] [34] . NO is not only a strong vasodilator but also an inhibitor of platelet aggregation, vascular smooth-muscle proliferation and leukocyte adhesion, all of which are strong antithrombotic and anti-atherogenic properties [28] [29] [30] [31] [32] [33] [34] . We tested NO production in EPCs with a bioassay using an organ chamber method (Fig. 2e) . To contract endothelia-denuded segments of guinea pig aorta, we used U46619, a thromboxane analog. We then exposed the segments to increasing concentrations of the calcium ionophore A23187 that was perfused through the EPCseeded graft in the same organ chamber. The aorta segments relaxed in a dose-dependent manner (Fig. 2e) , and this relaxation was significantly attenuated by adding 1 × 10 -3 M of the endothelial NO-synthase inhibitor L-NAME (77.5 % versus 58.5 %, P < 0.001; Fig. 2e ). When we perfused A23187 through grafts not seeded with EPCs, the aortic segments remained fully contracted (data not shown). Exposing the aortic segments to sodium nitroprusside (SNP), an endothelial-independent NO donor, resulted in a dose-dependent relaxation, indicating normal smooth-muscle function in the guinea pig aortic segments (Fig. 2e) . Together, these results showed that after preconditioning, the EPCs on the graft produced NO.
EPC-seeded grafts in vivo
To assess the efficacy of EPC-seeded grafts in vivo, we performed implantation studies in sheep. Autologous EPCs were isolated from 1-2-week-old lambs, expanded in culture, and seeded onto a decellularized graft. We then preconditioned the grafts over two days, gradually increasing shear stress from low to high. We implanted seeded (n = 7) and unseeded (n = 4) grafts, 4-5 cm in length, to replace a segment of the carotid artery using two endto-end anastomoses. The only anti-coagulant administered was daily aspirin (81 mg) for 7 days after the operations. All grafts showed unobstructed flow at the time of implantation. We performed ultrasound Doppler flow studies daily and carotid duplex studies two weeks postoperatively to assess patency, flow and thrombus formation. Of the four non-seeded control grafts, three occluded from thrombus formation within five days of implantation (Fig. 3) . One control graft was still patent when removed at 15 days, but 50% of the lumen was obstructed by thrombus upon carotid duplex imaging and histologic analysis. All the grafts seeded with the EPCs were fully patent at the time of removal, either 15 or 130 days after implantation (Fig. 3) . A representative arteriogram of a 130-day EPC-seeded explant shows a smooth luminal surface with no signs of thrombus, obstruction, or aneurysmal dilation (Fig. 4a) . A macroscopic view of the 130-day EPC-seeded explant confirms the smooth surface of the vessel lumen (Fig. 4b) .
Histological examination of the seeded grafts at 15 days revealed a confluent monolayer of endothelial cells (data not shown); however; there were minimal areas of the lumen that showed mild thrombus with cells concentrated at the thrombus- 
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graft interface (Fig. 4c) . The graft media was acellular. Histological examination of the entire length of the seeded grafts explanted at 130 days revealed cellular intimal thickening as possible pannus from the adjacent arterial segments, infiltration of cells into the graft media, minimal adventitial inflammatory response and a confluent flattened cell monoloayer lining the luminal surface of the graft (Fig. 4d) . Staining with Movat demonstrated preservation of the original anatomic features of the extracellular matrix, especially elastin (Fig. 4e) . The cells within the intimal layer stained positively for smooth-muscle α-actin, a characteristic of SMCs (Fig. 4f) , whereas those lining the luminal surface stained for vWF, a characteristic of endothelial cells (Fig. 4g) .
To determine if the seeded EPCs were still present on the graft at 130 days, we labeled the EPCs prior to seeding with a fluorescent lipophilic carbocyanine tracer that incorporates into cell membranes. Before implantation, the graft tissue sections showed a confluently labeled endothelial-cell layer (Fig. 4h) . After explantation, the grafts showed fluorescent EPCs that covered approximately 80% and 10% of the graft lumen, at 15 and 130 days, respectively ( Fig. 4i and j) . The low percentage of fluorescently labeled EPCs at 130 days might be due to dilution of the membraneincorporated dye with every cell division, which would suggest a high proliferation rate of the EPCs on the graft. Alternatively, some of the fluorescently labeled EPCs may have detached from the graft in vivo or the tracer dye might have diminished fluorescence at 130 days in vivo.
Because SMCs were present in the grafts, we evaluated the explanted graft for contraction and relaxation reactivity (Fig. 5) . We suspended the mid-segments of the 130-day explanted grafts in an organ chamber and measured contractility in response to norepinephrine and serotonin. The 130-day explanted grafts contracted in a dose-dependent manner to norepinephrine and serotonin with maximal responses of 65 and 335 respectively (Fig. 5a) . Compared with the explanted grafts, matched native carotid segments generated two-fold more force in response to serotonin and eight-fold more force contraction in response to norepinephrine. These results indicate that the vascular SMCs in the grafts are functional and respond to two physiologically important vasoconstrictors.
Increased endothelial NO production is associated with higher patency rates of coronary artery bypass arterial conduits, such as the radial artery or internal mammary artery 35, 36 . In an earlier set of experiments, we demonstrated the capacity of the EPC-seeded graft to produce NO in vitro (Fig. 2e) . To further assess the endothelial function of EPC-seeded grafts in an attempt to evaluate their long-term patency, we compared the endothelial-dependent relaxation of explanted 130 day EPC-seeded grafts with that of native sheep carotid artery and saphenous vein (Fig. 5b) . We pre-contracted segments of each vessel with serotonin and exposed them to increasing doses of acetylcholine to induce receptor-mediated NO production. Acetylcholine induced a dose-dependent relaxation in all three vessels (Fig. 5b) . Maximal relaxation of the EPC-seeded graft to acetylcholine was significantly greater than saphenous vein segments (68% ± 10% versus a b c d e 
22 ± 6%, P < 0.001), but similar to carotid artery (68% ± 10% versus 81 ± 8%, P = 0.088) (Fig. 5b) . The acetylcholine-induced dose-dependent relaxation of the explanted grafts was attenuated in the presence of the endothelial NO-synthase inhibitor L-NAME (68% ± 10% versus 22 ± 6%, P < 0.001) (Fig. 5b) . The three vessels responded equally to SNP (P = NS), an endothelial-independent NO donor, and achieved maximal relaxation, indicating normal vascular SMC function of the explanted 130-day EPC-seeded grafts (Fig. 5c) . Together, these results indicate that the endothelial-dependent and endothelial-independent vasomotor properties of the EPC-seeded grafts are similar to those of native carotid arteries; they may therefore have potentially long-term patency rates.
Discussion
Our results show that EPCs can be isolated from peripheral blood, expanded ex vivo and retained on a decellularized graft. Upon implantation in vivo, the EPCs provided an autologous, non-thrombogenic luminal surface that maintained patency for at least 130 days. Moreover, the EPC-seeded graft remodeled into a neovessel with vasomotor activity to physiological stimuli. The amount of NO production correlates strongly with patency rates of various vessel conduits used in bypass surgery 35, 36 . For instance, the internal mammary artery has greater endothelial-dependent relaxation mediated by NO than the saphenous vein, which may be involved in higher patency rates of internal mammary artery grafts 35 . We observed an endothelium-dependent relaxation of the 130-day explanted EPC-seeded grafts, which was comparable with native ovine carotid artery, but different from saphenous vein. We suggest this relaxation is dependent on NO production because the addition of L-NAME attenuated the relaxation. Similar studies using the same methodology have shown the internal mammary artery and radial artery to have enhanced NO-mediated relaxation compared with the saphenous vein, and this might contribute to the long-term patency of the internal mammary artery and radial artery grafts 36 . As some of the seeded EPCs were still present on the graft after 130 days in vivo, EPCs might have intrinsic physiological characteristics-including NO production-that contribute to the patency rate of the EPCseeded graft. This type of NO-mediated vascular relaxation might represent an advantage in using EPCs.
Further studies are needed to identify the source of the SMCs in the neo-intima of the vascular graft. One likely source is SMC migration across the anastomosis site from the adjacent artery; examination of sections from the anastomisis site suggests that SMCs might infiltrate the graft. Another potential source might involve transdifferentiation of the EPCs into SMCs. Transforming growth factor-β1 induces EPCs to express smoothmuscle α-actin in vitro (S.K. and J.B., unpublished data) suggesting EPCs are more plastic than mature, differentiated endothelium and might have more potential for remodeling the graft in vivo. A third potential source of SMCs may involve bonemarrow-derived mesenchymal stem cells, which have the potential to differentiate into smooth-muscle-like cells and might be recruited into the graft from the circulation 37 . More studies are required to understand the vascular biology of the neo-intima formation on the decellularized graft in vivo.
Here we demonstrate the benefit of endothelializing vascular grafts for long-term patency. In the past, much effort has focused on endothelializing ePTFE grafts to increase their long-term patency in humans 38 . Previously, the endothelial source for seeding grafts has been biopsies from existing blood vessels. Because EPCs can be obtained non-invasively from relatively small amounts of the patient's peripheral blood, this technique might eliminate the need to remove healthy vessels for collecting autologous endothelial cells. In addition, EPCs might have broader clinical applications for tissue-engineering structures that require an endothelial lining, such as heart valves. Another application of the EPCs might be engineering of the cells ex vivo to express specific genes for medical conditions and re-introducing them into selected areas of the body, for instance, ischemic myocardium. We have observed that EPCs are easily infected with a retrovirus and stably express the transgene in vitro (S.K. and J.B., unpublished data). Eventually EPCs might provide a wide variety of therapeutic options for patients.
The EPC-seeded grafts develop into neovessels in vivo by 130 days and exhibited NO-mediated vascular relaxation. Our study was limited by the size of the study groups and the limited number of intervals that we examined in vivo. Long-term studies will be necessary to determine whether aneurysmal dilation, thrombus formation, hyperplasia of the neo-intima or other processes might impair the function of the neovessel. Our combined approach of seeding EPCs on a decellularized graft or other vascular grafts might be an attractive approach for tissue engineering small-diameter blood vessels. In addition, due to their physiological properties and easy accessibility, EPCs may have broad applications for treating vascular diseases.
Methods
Isolation of EPCs from peripheral blood. EPCs were collected from the internal jugular vein of 1-to 2-week-old sheep as described 9 . After the initial 5 cc of blood was discarded, 15 cc of blood was mixed with 100 U heparin. The leukocyte fraction was obtained by centrifuging on a Histopaque density gradient (Sigma) for 30 min at 1000g using Accuspin tubes (Sigma). The cell pellet was resuspended in EBM-2 medium (Clonetics, San Diego, California), with 20% FCS (Hyclone, Logan, Utah) but without hydrocortisone, and plated on fibronectin-coated plates. At 24-h intervals for the next 3 d, the medium was transferred to new fibronectin-coated plates and thereafter the media was changed every 3 d. An aliquot of cells in the medium on day 3 was counted to determine input cells for final plating.
Indirect immunoflourence. Indirect immunoflourence was performed as described 27 using antibodies against CD31 (Santa Cruz Biotechnology, Santa Cruz, California), vWF (DAKO, Carpenteria, California) and E-selectin (NeoMarkers, Freemont, California), and imaged for incorporation with fluorescent aLDL (Biomedical Technologies, Stoughton, Massachusetts). Cells were analyzed using a Zeiss Axiphot II fluorescence microscope and photographed using Ektachrome p1600 color slide film.
Western-blot analysis. Cell lysates were prepared as described 39 and separated by SDS-PAGE and transferred to Immobilon-P membrane. Anti-KDR and anti-Tie-2 antibodies (Santa Cruz Biotechnology, Santa Cruz, California) were used to detect these endothelial specific proteins.
Decellularized graft preparation. Freshly collected porcine iliac blood vessels were placed in distilled water for 1 h to remove blood elements. The vessels were then placed into a decellularizing solution containing 1% Triton X-100 and 0.1% ammonium hydroxide (Sigma) in PBS (500 ml) and placed on a mechanical shaker (120 revolutions per minute) at 4°C for 72 hours. The solution was changed every 24 h. After cleaning, the vessels were lyophilized and cold-gas sterilized.
Isometric studies. All isometeric tension experiments were performed as described 36 . Guinea pig aortic rings were suspended between 2 tungsten stirrups in an organ chamber bath of oxygenated Krebs solution maintained at 37 °C. The vessels were increasingly stretched by 0.1-g increments to the optimal resting tension that produced a maximal response to 80 mmol/L KCl and allowed to relax for 1 h. EPC-seeded grafts were directly attached to the aortic ring. After U46619 contraction of the aortic ring, relaxation of the aor-
